Biodesix INC 10-Q quarterly reports

Biodesix, Inc. reported a 20% increase in total revenue for the third quarter of 2025, driven by strong growth in both diagnostic tests and development services, while also narrowing its net loss.

Biodesix, Inc. reported a 12% increase in second-quarter revenue, driven by strong growth in diagnostic tests and development services, but faces a Nasdaq delisting notice and increased net loss for the quarter.

Biodesix reports a 21% increase in revenue for Q1 2025 and secures an additional $10 million loan while addressing Nasdaq compliance.

Biodesix, a lung disease diagnostics company, announced a 35% year-over-year revenue increase in the third quarter of 2024, primarily driven by strong growth in its lung diagnostic testing segment.

Biodesix's Q2 2024 revenue increased by 51% year-over-year, fueled by growth in both lung diagnostic testing and biopharmaceutical services.

Biodesix's first quarter 2024 results show a significant 64% increase in total revenue, driven by growth in both lung diagnostic testing and biopharmaceutical services.